These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

996 related articles for article (PubMed ID: 23466967)

  • 1. Recent advances in antithrombotic therapy for stroke prevention in patients with atrial fibrillation.
    Lenchus JD
    Hosp Pract (1995); 2013 Feb; 41(1):49-60. PubMed ID: 23466967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study.
    Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Thromb Haemost; 2012 Mar; 107(3):584-9. PubMed ID: 22186961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J; Marx S; Diener HC; Lip GY; Marder VJ; Wehling M; Weiss C
    Int Angiol; 2012 Aug; 31(4):330-9. PubMed ID: 22801398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.
    Contractor T; Levin V; Martinez MW; Marchlinski FE
    Postgrad Med; 2013 Jan; 125(1):34-44. PubMed ID: 23391669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation.
    Galanis T; Merli GJ
    Hosp Pract (1995); 2013 Feb; 41(1):26-36. PubMed ID: 23466965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
    Pisters R; Nieuwlaat R; Lane DA; Crijns HJ; Lip GY
    Thromb Haemost; 2013 Feb; 109(2):328-36. PubMed ID: 23179181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers.
    Fanikos J
    J Med Econ; 2013 Oct; 16(10):1190-2. PubMed ID: 23919663
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Ahmad Y; Lip GY
    Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
    Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 50.